COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cognitive Rehabilitation of Glioma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00256425
Recruitment Status : Unknown
Verified July 2007 by UMC Utrecht.
Recruitment status was:  Active, not recruiting
First Posted : November 21, 2005
Last Update Posted : March 21, 2008
Dutch Cancer Society
Information provided by:
UMC Utrecht

Brief Summary:
The purpose of this study is to determine whether cognitive rehabilitation is effective in patients with gliomas (brain tumour), by comparing direct and follow-up neuropsychological functioning and quality of life of the experimental group to the control group.

Condition or disease Intervention/treatment Phase
Glioma Cognition Disorders Behavioral: Cognitive rehabilitation Phase 3

Detailed Description:

The majority of patients with (low-grade) glioma exhibit cognitive symptoms and objective deficits, which have a sustained, negative impact on daily functioning and quality of life.

Adult patients with a low-grade glioma, either histologically proven, or suspected (1), as well as adult anaplastic glioma patients with favorable prognostic factors (2), who are clinically stable for at least 6 months, will be recruited from 9 hospitals in the Netherlands. Consenting patients with both subjective cognitive symptoms and objective deficits will be randomized to either the cognitive rehabilitation program (N = 75) or a "waiting-list" control group (N = 75). Upon completion of the study, those patients assigned to the control group will be given the opportunity to undergo the cognitive rehabilitation program.

The cognitive rehabilitation program incorporates both retraining of impaired cognitive functions, and teaching of compensatory strategies. Rehabilitation will be directed towards attention, memory and executive functioning. The intervention will consist of 6 weekly, individual, 2-hour sessions plus two hours of homework.

To evaluate the efficacy of the rehabilitation program, objective neuropsychological functioning, self-reported cognitive symptoms and health-related quality of life will be assessed before rehabilitation, directly following rehabilitation, and at 6-month follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study
Study Start Date : October 2003
Estimated Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rehabilitation

Primary Outcome Measures :
  1. neuropsychological measures of attention (test scores) [ Time Frame: baseline, immediately after 6 weeks and at 6-month follow-up ]

Secondary Outcome Measures :
  1. neuropsychological measures of memory and executive functioning (test scores) [ Time Frame: baseline, immediately after 6 weeks and at 6-month follow-up ]
  2. subjective neuropsychological functioning (questionnaires) [ Time Frame: baseline, immediately after 6 weeks and at 6-month follow-up ]
  3. quality of life (questionnaires) [ Time Frame: baseline, immediately after 6 weeks and at 6-month follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients with a histologically proven low-grade glioma or presumed (i.e., suspected) low-grade glioma based on both clinical and MR imaging feature, and
  • adult patients with an anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligo-astrocytoma) under age 50 and with good performance status (KPS > 70);
  • who are clinically stable for a minimum of 6 months prior to study entry (as determined by recent CT or MRI imaging) and no anti-tumor treatment during that period of time (i.e., surgery, radiotherapy, chemotherapy, corticosteroids);
  • who report at least one symptom of impaired cognitive functioning based on a standardized self-report questionnaire, administered by researcher;
  • and who meet criteria for neuropsychological impairment based on objective test results (assessed by researcher).

Exclusion Criteria:

  • lack of basic proficiency in Dutch;
  • IQ below 85;
  • severe reading problems;
  • an additional (history of) neurological or psychiatric disorder;
  • participating in a concurrent study in which neuropsychological testing and/or health-related quality of life assessments are involved

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00256425

Layout table for location information
VU Medical Center
Amsterdam, Netherlands, 1007 MB
Netherlands Cancer Institute
Amsterdam, Netherlands, 1066 CX
Medical Center Haaglanden
Den Haag, Netherlands, 2501 CK
UMC Groningen
Groningen, Netherlands, 9700 RB
AZ Maastricht
Maastricht, Netherlands, 6202 AZ
UMC St Radboud
Nijmegen, Netherlands, 6500 HB
Erasmus Medical Center
Rotterdam, Netherlands, 3008 AE
Sint Elisabeth Hospital
Tilburg, Netherlands, 5000 LC
University Medical Center Utrecht
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
UMC Utrecht
Dutch Cancer Society
Layout table for investigator information
Principal Investigator: Martin JB Taphoorn, MD, PhD Medical Center Haaglanden
Principal Investigator: Neil K Aaronson, PhD The Netherlands Cancer Institute
Principal Investigator: Margriet M Sitskoorn, PhD UMC Utrecht
Layout table for additonal information Identifier: NCT00256425    
Other Study ID Numbers: UU 2003-2783
First Posted: November 21, 2005    Key Record Dates
Last Update Posted: March 21, 2008
Last Verified: July 2007
Keywords provided by UMC Utrecht:
brain tumor
executive function
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognition Disorders
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neurocognitive Disorders
Mental Disorders